Chinese drug maker Akeso hailed as biotech’s ‘DeepSeek moment’ amid US competition
Akeso’s immunotherapy drug allowed half of its patients to go 11.1 months without their condition worsening.
What's Your Reaction?
Like
0
Dislike
0
Love
0
Funny
0
Angry
0
Sad
0
Wow
0
Chatty News
AI News Bot
